Failure Points: Risk Analysis in Biopharma & Pharmaceutical R&D / QC Laboratories
Biopharma and pharmaceutical laboratories in Pakistan face regulatory-driven risk, not because analytical science is weak, but because documentation, traceability, and change control break down under real operational pressure. This page identifies where failures actually occur, why they occur, and why even rare lapses can trigger critical regulatory observations, batch delays, or compliance actions.
Sample Misclassification Across Lifecycle Stages
Where failures occur
During receipt and handling of development, validation, routine QC, and stability samples.
Why they occur
- Similar sample names across stages
- Manual tracking on worksheets or Excel
- Analysts handling multiple project types simultaneously
Impact
Testing a development or validation sample as routine QC (or vice versa) invalidates data packages and can compromise regulatory submissions.
Frequency vs severity
- Frequency : Medium
- Severity : High
Weak Linkage Between Raw Data, Worksheets, and Final Results
Where failures occur
Between instrument output, calculations, and reported results
Why they occur
- Standalone instrument software
- Manual transcription into Excel
- Separate QA review folders
Impact
During audits, inability to clearly link raw data → calculation → approval is treated as a data integrity failure, regardless of result correctness.
Frequency vs severity
- Frequency : High
- Severity : High
Undocumented Method Changes and Deviations
Where failures occur
During method development, optimization, or routine troubleshooting.
Why they occur
- Pressure to meet timelines
- Informal adjustments by experienced analysts
- Delayed or incomplete deviation documentation
Impact
Undocumented method changes undermine method validity and can invalidate entire data sets during inspection.
Frequency vs severity
- Frequency : Low-Medium
- Severity : Critical
Instrument Qualification and Calibration Gaps
Where failures occur
Across routine analytical operations.
Why they occur
- Calibration records stored separately
- Qualification status not visible at time of testing
- Retrospective verification during audits
Impact
Data generated on unqualified or expired instruments is considered non-defensible, even if results meet specifications.
Frequency vs severity
- Frequency : Low
- Severity : Critical
Manual Data Transcription and Calculation Errors
Where failures occur
During result calculation, reporting, and summary preparation.
Why they occur
- Excel-based calculations
- Copy-paste from instrument outputs
- Limited version control
Impact
Transcription or calculation errors lead to rework, investigation, and loss of audit confidence.
Frequency vs severity
- Frequency : High
- Severity : High
Stability Study Tracking and Time-Point Errors
Where failures occur
During long-term and accelerated stability programs.
Why they occur
- Manual scheduling of pull points
- Weak parent–child sample linkage
- Separate tracking sheets for each study
Impact
Missed or incorrect stability time points invalidate shelf-life claims and trigger regulatory findings.
Frequency vs severity
- Frequency : Low
- Severity : Critical
Fragmented Documentation Across R&D, QC, and QA
Where failures occur
Across departments handling the same data set.
Why they occur
- Paper files in labs
- Excel sheets for calculations
- QA-controlled archives elsewhere
Impact
Reconstructing a complete data trail during inspections becomes slow, inconsistent, and error-prone.
Frequency vs severity
- Frequency : Medium
- Severity : High
In pharma labs, one undocumented change, one missing raw data file, or one calibration lapse outweighs hundreds of compliant tests. Regulators interpret such failures as systemic data governance weakness, not isolated mistakes.